Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Pfizer reveals easing of fourth quarter revenue

“I was pleased with the company’s overall performance during 2016," said chief executive Ian Read.
Pfizer corporate headquarters in New York
Pfizer generated US$13.6bn of revenue in the fourth quarter

Dollar strength was one of the reasons given as Pfizer Inc (NYSE: PFE) revealed a reduction in the fourth quarter financials.

The drug Viagra and Lyrica maker generated US$13.6bn of revenue, down 3% compared to US$14bn in the same three months of 2015.

Over the full year revenues amounted to US$52.8bn which was an 11% increase from US$48.8bn.

“Pfizer-standalone revenues in 2016 grew 5% operationally, excluding the impact of foreign exchange as well as legacy Hospira and legacy Medivation operations, reflecting solid underlying growth despite significant headwinds from product losses of exclusivity and the decline in revenues for Prevnar 13 Adult in the US,” said chief financial officer Frank D’Amelio.

Meanwhile, chief executive Ian Read added: “I was pleased with the company’s overall performance during 2016 and believe both of our businesses executed well despite a challenging operating environment.

“We generated attractive operational revenue and earnings growth driven by our major products within both the Innovative Health and Essential Health businesses.”

View full PFE profile View Profile

Pfizer Timeline

Article
November 23 2015

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use